Adaptive Biotechnologies (ADPT) Q3 2023: MRD Clinical Volumes Up 56%, Strategic Review Signals Business Split
Adaptive Biotechnologies’ Q3 marked a turning point as management launched a formal strategic review to separate its two core businesses, driven by diverging maturity and capital needs. MRD clinical testing volumes surged 56% year over year, but pharma service headwinds and immune medicine’s evolving drug discovery focus prompted guidance changes and operational streamlining. Investors now face a business in transition, with a clear path to MRD profitability and a reset on immune medicine’s revenue outlook.
Summary
- MRD Diagnostic Focus Intensifies: Leadership commits to maximizing MRD’s commercial potential and profitability, decoupling from immune medicine.
- Immune Medicine Shifts to Long-Term Value: Strategic review pivots immune medicine to a biotech model, removing short-term revenue guidance.
- Operational Leverage and ASP Initiatives: Cost actions and pricing levers position MRD for margin gains and standalone scale.
Business Overview
Adaptive Biotechnologies operates two distinct businesses: MRD (Minimal Residual Disease) diagnostics, anchored by ClonoSeq, which provides molecular tests for hematologic cancers, and immune medicine, focused on drug discovery for autoimmune and oncology indications. MRD generates revenue through clinical testing for physicians and pharma services for biopharma partners, while immune medicine monetizes via partnerships and milestone payments, now pivoting toward a traditional biotech model emphasizing asset development and licensing.
Performance Analysis
Q3 results highlight strong operational execution in MRD clinical testing, with volumes up 56% year over year, reaching over 15,000 tests. Growth was broad-based, led by multiple myeloma and increased adoption in community settings, which now represent 21% of ClonoSeq volume, up from 13% a year ago. Blood-based testing contributed 36% of MRD tests, underscoring the shift toward less invasive modalities and supporting future expansion.
Despite robust clinical trends, MRD pharma revenue fell 4% year over year due to macro-driven biopharma reprioritizations, resulting in lower sample volumes and delayed studies. Immune medicine revenue declined sharply, reflecting lower milestone recognition and a move away from short-term service revenue. Gross margin compressed to 49%, impacted by reduced high-margin milestone revenue and one-time lab move costs, though underlying margin excluding these items was 55%. Operating expenses declined by double digits, demonstrating cost discipline.
- Volume Expansion Outpaces Market: ClonoSeq’s 56% test growth signals deepening clinical adoption and competitive moat in MRD.
- Pharma Services Drag: Biopharma budget tightening and study delays weighed on pharma segment, but backlog remains robust at $190 million.
- Margin Leverage Emerging: Operational initiatives, including lab consolidation and LIMS upgrade, set up MRD for 70%+ gross margin at scale.
Cash position remains strong at $371 million, supporting execution through the transition and strategic review. The business is positioned for MRD profitability by 2025, while immune medicine’s reset shifts focus to long-term asset value.
Executive Commentary
"This quarter marks a pivotal moment in Adaptive's evolution. As we have previously shared, we have two compelling businesses in MRD and immune medicine. They are at disparate stages of maturity with different investment requirements, operating models, and distinct value drivers. To maximize the full potential of each business, we have hired Goldman Sachs to assist with a review of strategic alternatives. We will provide clarity on the path forward by early next year."
Chad Robbins, CEO and Co-founder
"The MRD business overall has been strong, driven by high-volume growth of ClonoSeq. We continue to focus on optimizing operations to further enhance margins. This includes the implementation of a new LIMS ecosystem by mid-2024, which will allow us to reduce overhead and increase the productivity of direct labor in the lab."
Tycho Peterson, Chief Financial Officer
Strategic Positioning
1. Formal Strategic Review to Separate Businesses
Management’s engagement of Goldman Sachs to evaluate strategic alternatives signals a likely decoupling of MRD and immune medicine. This move reflects their fundamentally different capital requirements and maturity—MRD as a commercial diagnostics platform and immune medicine as a long-horizon drug discovery engine. The review is expected to yield clarity by early 2024, with options ranging from spin-outs to asset sales or independent public listings.
2. MRD Focused on Scale, Profitability, and Penetration
MRD is positioned as a pure-play diagnostics business with a leading market share and strong clinical momentum. The focus is on driving test volumes, expanding blood-based and community segments, and optimizing average selling prices (ASPs) through payer mix and operational enhancements. Leadership targets profitability by 2025, supported by scale-driven margin leverage and operational streamlining.
3. Immune Medicine Pivoting to Asset-Driven Biotech Model
Immune medicine is shifting away from near-term revenue in favor of long-term asset value creation, as evidenced by the withdrawal of short-term revenue guidance. The business achieved a key milestone with the discovery of a novel multiple sclerosis target, validating its AI-enabled TCR discovery platform. Future monetization will depend on pipeline advancement and strategic partnerships, not service revenue.
4. Operational Leverage and Technology Upgrades
Cost actions—including lab consolidation, LIMS implementation, and a sequencer platform switch—are set to unlock significant margin improvement. Management expects these initiatives to drive the MRD business to 70%+ gross margin at scale, with cash burn normalizing and operating expenses declining.
5. Pharma Backlog and Adjacency Expansion
Despite near-term pharma headwinds, a $190 million MRD pharma backlog and plans to expand into new hematologic indications provide visibility for future growth. Management is also exploring myeloid and solid tumor adjacencies, though near-term focus remains on core heme malignancies and reimbursement expansion.
Key Considerations
This quarter’s developments reposition Adaptive as two distinct investment stories, each with unique risk-reward profiles and operational levers. The MRD business is approaching a scale inflection, while immune medicine’s value will hinge on clinical and partnership milestones.
Key Considerations:
- Strategic Decoupling Unlocks Focus: Resource competition between MRD and immune medicine has limited each unit’s growth; separation could accelerate both.
- MRD ASP and Volume Levers: Ongoing payer mix optimization, new CPT codes, and Epic EMR integrations should drive sustainable ASP and volume gains.
- Pharma Services Remain Volatile: Biopharma budget cycles and portfolio reprioritizations could continue to pressure pharma revenue, despite backlog strength.
- Immune Medicine Monetization Uncertain: Long-term value depends on successful clinical progression and strategic partnerships, with no near-term revenue visibility.
- Cash Burn and Margin Trajectory: Cost actions are critical to achieving MRD profitability and preserving optionality for immune medicine investment.
Risks
Key risks include continued biopharma spending softness impacting pharma services, execution risk in scaling MRD volumes and ASPs, and uncertainty around the monetization timeline for immune medicine. The strategic review introduces potential disruption, and a business split may expose each segment to market and operational risks previously absorbed by the combined entity. Regulatory and reimbursement shifts in diagnostics, as well as competitive advances in MRD or TCR discovery, remain ongoing external threats.
Forward Outlook
For Q4 and full-year 2023, Adaptive guided to:
- MRD clinical test volumes growing over 50% year over year
- Mid-single-digit sequential ASP growth in Q4
- Pharma services to remain under pressure with continued biopharma spending headwinds
- Full-year MRD revenue of $100 to $105 million
- Total company OpEx, including cost of revenue, targeted at $375 million for the year
Management expects MRD profitability by 2025 and sees a strong pharma backlog fueling future growth. Immune medicine revenue guidance is withdrawn, with future value dependent on pipeline milestones and partnerships. The strategic review outcome will set the course for both businesses in 2024 and beyond.
Takeaways
Adaptive’s Q3 marks a strategic inflection, with the business preparing for a likely split and a sharper focus on MRD’s path to profitability and immune medicine’s long-term asset value.
- MRD Clinical Momentum: Sustained test volume growth and ASP improvement position MRD for standalone scale and margin expansion.
- Immune Medicine Reset: Withdrawal of revenue guidance underscores a pivot to biotech risk-reward, with value realization tied to clinical milestones and partnerships.
- Watch for Strategic Review Outcome: Investors should monitor the resolution of the business split, progress on MRD margin and volume levers, and immune medicine’s clinical data flow in 2024.
Conclusion
Adaptive Biotechnologies is at a crossroads, with Q3’s results and strategic review signaling a future of focused, independent businesses. MRD’s commercial momentum and operational leverage offer a clear path to profitability, while immune medicine’s asset-driven strategy will require patience and clinical validation. The coming quarters will clarify each segment’s standalone trajectory and value proposition.
Industry Read-Through
Adaptive’s experience highlights the challenges of operating hybrid diagnostics and drug discovery platforms within a single corporate structure. The move to separate businesses reflects a broader trend of specialization and focus in both diagnostics and biotech, as capital markets increasingly reward clear business models and execution. Biopharma services headwinds are not unique to Adaptive, signaling ongoing caution for peers exposed to pharma R&D cycles. MRD’s volume and ASP levers—especially payer mix and EMR integration—offer a playbook for diagnostics players seeking margin expansion. The immune medicine pivot underscores the long and uncertain road to monetization in novel target discovery, with value realization tied to clinical and partnership inflections rather than near-term revenue.